Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-004503-39
    Sponsor's Protocol Code Number:IG1104
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2014-10-06
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2013-004503-39
    A.3Full title of the trial
    A multicenter, prospective, randomized, placebo-controlled, double-blind,
    parallel-group clinical trial to assess the efficacy and safety of Immune Globulin
    Intravenous (Human) Flebogamma® 5% DIF in patients with Post-Polio
    Syndrome
    Sperimentazione clinica multicentrica, prospettica, randomizzata, controllata con placebo, in doppio cieco, a gruppi paralleli per valutare l'efficacia e la sicurezza dell'immunoglobulina (umana) per via endovenosa Flebogamma® 5% sottoposta a doppia inattivazione e nanofiltrata (Dual Inactivation Plus Nanofiltration, DIF) in pazienti affetti da sindrome post-polio.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to evaluate the safety and efficacy of Flebogamma 5% DIF in patients with Post-Polio Syndorme
    Studio per valutare la sicurezza e l'efficacia di Flebogamma 5% DIF in pazienti affetti da sindrome post-polio.
    A.4.1Sponsor's protocol code numberIG1104
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorInstituto Grifols, S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportInstituto Grifols, S.A.
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationInstituto Grifols, S.A.
    B.5.2Functional name of contact pointDepartment of Clinical Trials
    B.5.3 Address:
    B.5.3.1Street AddressAv. Generalitat 152
    B.5.3.2Town/ citySant Cugat del Vallès (Barcelona)
    B.5.3.3Post code08174
    B.5.3.4CountrySpain
    B.5.4Telephone number34935712000
    B.5.5Fax number34935712482
    B.5.6E-mailIGregulatory.affairs@grifols.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Flebogamma DIF 50 mg/ml - 200 ml
    D.2.1.1.2Name of the Marketing Authorisation holderInstituto Grifols, S.A.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman normal immunoglobulin (IVIg)
    D.3.9.3Other descriptive nameHUMAN NORMAL IMMUNOGLOBULIN (IV)
    D.3.9.4EV Substance CodeSUB12041MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Yes
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with Post-polio syndrome
    Pazienti con Sindrome post-polio (Post-Polio Syndrome, PPS)
    E.1.1.1Medical condition in easily understood language
    Therapy for subjects suffering post-poliomyelitis syndorme
    Terapia per soggetti affetti da Sindrome post-polio
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.0
    E.1.2Level PT
    E.1.2Classification code 10036239
    E.1.2Term Post polio syndrome
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.0
    E.1.2Level SOC
    E.1.2Classification code 10029205
    E.1.2Term Nervous system disorders
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the safety and efficacy of Flebogamma 5% DIF in patients with post-polio syndrome
    per valutare la sicurezza e l'efficacia di Flebogamma® 5% sottoposta a doppia inattivazione e nanofiltrata (Dual Inactivation Plus Nanofiltration, DIF) in pazienti affetti da sindrome post-polio.
    E.2.2Secondary objectives of the trial
    To evaluate clinical effect of Flebogamma 5%DIF in PPS subjects by:
    - assessing pain , as measured by VAS of pain, compared to that of placebo
    - evaluating health-related quality of life (HRQoL), as measured by SF-36 PCS, compared to that of placebo
    - endurance, as measured by 6MWD, compared to that of placebo.
    per valutare gli effetti clinici di Flebogamma 5%DIF in in pazienti affetti da sindrome post-polio.
    - la valutazione del dolore, come misurato dalla Scala analogica Visiva del dolore ,comparato al placebo
    -la valutazione della salute-qualità della vita (HRQoL) come misurata da SF-36 PCS, comparata al placebo
    - la resistenza , come misurata da 6MWD, comparata al placebo
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Clinical trial subject inclusion criteria:
    1. Male or female aged 18 to 75 years.
    2. Subjects who understand and voluntarily signed and dated
    the Clinical Trial Written Informed Consent Form for
    his/her clinical trial participation.
    3. Subjects with a BMI less than 30 kg/m2.
    4. Subjects who meet the clinical criteria for diagnosis of PPS
    as set by the March-of-Dimes.
    5. Subjects who are ambulatory or are able to walk with a cane
    or other aids.
    6. Subjects who have at least two newly weakened muscle
    groups, and one of them in a lower extremity, as defined by
    medical history and having a mMRC scale score of 3 or
    greater at the SV.
    7. Female subjects of child-bearing potential must have a
    negative test for pregnancy (human chorionic gonadotropin [HCG]-based assay).
    8. Female subjects of child-bearing potential and their sexual
    partners have agreed to practice contraception using a
    method of proven reliability (i.e., hormonal methods; barrier
    methods; intrauterine devices methods) to prevent a
    pregnancy during the course of the clinical trial.
    9. Subjects must be willing to comply with all aspects of the
    clinical trial protocol, including blood sampling and
    long-term storage of extra samples for the whole duration of
    the study.
    10. Subjects who are able to walk a 2MWD of at least 50 meters
    at the Screening Visit (SV) and EV/IV1.
    11. Subjects who are able to walk a consistent baseline 2MWD,
    that is, the difference in 2MWD between the SV and EV/IV1
    is not more than 10%.
    Criteri di inclusione
    1.Soggetti di sesso maschile e femminile di età compresa tra 18 e 75 anni
    2.Soggetti capaci di intendere e di volere che firmino e datino il Modulo di consenso informato scritto di partecipazione alla sperimentazione clinica per la propria partecipazione alla sperimentazione clinica.
    3.Soggetti con un IMC inferiore a 30 kg/m2.
    4.Soggetti che soddisfino i criteri clinici per la diagnosi di PPS, come stabiliti dal “March of Dimes”.
    5.Soggetti deambulanti o in grado di camminare con un bastone o altri ausili.
    6.Soggetti che abbiano almeno due gruppi muscolari recentemente indeboliti, di cui uno sia un arto inferiore, come definito dall'anamnesi medica e che presentino un punteggio della scala mMRC pari o superiore a 3 alla SV.
    7.Soggetti di sesso femminile in età fertile con un risultato negativo al test di gravidanza (dosaggio quantitativo della gonadotropina corionica umana [Human Chorionic Gonadotropin, HCG] nel siero).
    8.Soggetti di sesso femminile in età fertile che, unitamente ai propri partner sessuali, abbiano accettato di praticare la contraccezione utilizzando un metodo di comprovata affidabilità (ossia, metodi ormonali, metodi barriera o metodi con dispositivi intrauterini) al fine di prevenire una gravidanza nel corso della sperimentazione clinica.
    9.Soggetti disposti a rispettare tutti gli aspetti del protocollo di sperimentazione clinica, tra cui il campionamento di sangue e la conservazione a lungo termine di campioni supplementari per tutta la durata dello studio.
    10.Soggetti in grado di camminare per una distanza di almeno 50 metri al test 2MWD eseguito alla visita di screening (SV)e alla EV/IV1
    11.Soggetti in grado di camminare per una distanza regolare al test 2MWD al basale, ossia una differenza al test 2MWD tra la SV e la EV/IV1 non superiore al 10%.
    E.4Principal exclusion criteria
    Clinical trial subject exclusion criteria:
    1. Subjects who have received immune globulin treatment
    given by intravenous, subcutaneous or intramuscular route
    within the last 3 years.
    2. Subjects who are not ambulatory (wheelchair-bound
    individuals).
    3. Subjects with poor venous access.
    4. Subjects with intractable pain requiring narcotics or other
    psychotropic drugs.
    5. Subjects with a history of anaphylactic reactions or severe
    reactions to any blood-derived product.
    6. Subjects with a history of intolerance to any component of
    the investigational products, such as sorbitol.
    7. Subjects who are receiving corticosteroids, except for those
    who are taking them for asthma.
    8. Subjects with a documented diagnosis of hyperviscosity or
    hypercoagulable state or thrombotic complications to
    polyclonal IVIG therapy in the past.
    9. Subjects with a history of recent (within the last year)
    myocardial infarction, stroke, or uncontrolled hypertension.
    10. Subjects who suffer from congestive heart failure, embolism,
    or ECG changes indicative of unstable angina or atrial
    fibrillation.
    11. Subjects with a history of chronic alcoholism or illicit drug
    abuse (addiction) in the preceding 12 months prior to the SV.
    12. Subjects with active psychiatric illness that interferes with
    compliance or communication with health care personnel.
    13. Subjects with depression with scores >30 as assessed by the
    CESD validated scale.
    14. Females who are pregnant or are nursing an infant child.
    15. Subjects with any medical condition which makes clinical
    trial participation unadvisable or which is likely to interfere
    with the evaluation of the study treatment and/or the
    satisfactory conduct of the clinical trial according to the
    Investigator’s judgment.
    16. Subjects currently receiving, or have received within 3
    months prior to the Screening Visit, any investigational
    medicinal product or device.
    17. Subjects who are unlikely to adhere the protocol
    requirements, or are likely to be uncooperative, or unable to
    provide a storage serum/plasma sample prior to the first
    investigational drug infusion.
    18. Subjects with a known selective IgA deficiency and serum
    antibodies anti-IgA.
    19. Subjects with renal impairment (i.e., serum creatinine
    exceeds more than 1.5 time the upper limit of normal [ULN]
    for the expected normal range for the testing laboratory).
    20. Subjects with AST or ALT levels exceeding more than 2.5
    times the ULN for the expected normal range for the testing
    laboratory.
    21. Subjects with hemoglobin levels <10 mg/dL, platelets levels
    <100,000/mm3, white blood cells count <3.0 k/μL and ESR
    >50 mm/h or twice above normal.
    22. Subjects with known seropositive to HCV, HIV-1 and/or
    HIV-2.
    Criteri di esclusione
    1.Soggetti che abbiano ricevuto un trattamento con immunoglobuline per via endovenosa, sottocutanea o intramuscolare negli ultimi 3 anni.
    2.Soggetti che non siano deambulanti (persone in sedia a rotelle).
    3.Soggetti con scarso accesso venoso.
    4.Soggetti con dolore intrattabile che richieda l'assunzione di narcotici o altre sostanze psicotrope.
    5.Soggetti con un'anamnesi di reazioni anafilattiche o reazioni gravi a qualsiasi prodotto di derivazione ematica.
    6.Soggetti con un'anamnesi di intolleranza a qualsiasi componente dei prodotti sperimentali, come il sorbitolo.
    7.Soggetti che ricevano corticosteroidi, ad eccezione di quelli che li stanno assumendo contro l'asma.
    8.Soggetti con una diagnosi documentata di iperviscosità o stato di ipercoagulabilità o complicanze trombotiche alla terapia con IVIG policlonali in passato.
    9.Soggetti con un'anamnesi recente (entro l'anno precedente) di infarto miocardico, ictus o ipertensione non controllata.
    10.Soggetti che soffrano di insufficienza cardiaca congestizia, embolia o alterazioni dell'ECG indicative di angina instabile o fibrillazione atriale.
    11.Soggetti con un'anamnesi di alcolismo cronico o abuso di sostanze stupefacenti (dipendenza) nei 12 mesi precedenti la SV.
    12.Soggetti con malattia psichiatrica attiva che interferisca con la conformità o la comunicazione con il personale sanitario.
    13.Soggetti con punteggi >30 relativi alla depressione, secondo la valutazione mediante la scala convalidata dal CESD.
    14.Soggetti di sesso femminile che siano in gravidanza o stiano allattando un neonato al seno.
    15.Soggetti con qualsiasi condizione medica che renda sconsigliabile la partecipazione alla sperimentazione clinica o che possa interferire con la valutazione del trattamento dello studio e/o la conduzione soddisfacente della sperimentazione clinica secondo il giudizio dello sperimentatore.
    16.Soggetti che stiano ricevendo, o abbiano ricevuto nei 3 mesi precedenti la visita di screening, qualsiasi prodotto medicinale o dispositivo sperimentale.
    17.Soggetti che possano difficilmente rispettare i requisiti del protocollo, o che siano suscettibili di essere scarsamente collaborativi, o che non siano in grado di fornire un campione di siero/plasma destinato alla conservazione nel periodo precedente la prima infusione del farmaco sperimentale.
    18.Soggetti con un deficit selettivo confermato di IgA e anticorpi anti-IgA.
    19.Soggetti affetti da insufficienza renale (ossia, con livelli sierici di creatinina 1,5 volte maggiori rispetto al limite superiore di normalità [LSN] per l'intervallo di normalità previsto per il laboratorio di analisi).
    20.Soggetti con livelli di AST o ALT 2,5 volte maggiori rispetto all'LSN per l'intervallo di normalità previsto per il laboratorio di analisi.
    21.Soggetti con livelli di emoglobina <10 mg/dl, livelli di piastrine <100.000/mm3, conta dei globuli bianchi <3,0 k/µl e velocità di eritrosedimentazione (VES) >50 mm/h o due volte maggiori rispetto alla norma.
    22.Soggetti con sieropositività confermata a HCV, HIV-1 e/o HIV-2.
    E.5 End points
    E.5.1Primary end point(s)
    To test whether monthly infusions (every four weeks) of
    intravenous Flebogamma® 5% DIF in a 1 year treatment period
    in PPS subjects are superior to placebo by assessing physical
    performance, as measured by 2MWD (2-minutes walk distance)
    For Stage 1, to select the optimal dose of IVIG as compared to
    the placebo.
    For Stage 2, to establish superiority of the selected dose of IVIG
    as compared to placebo by combining both Stage 1 and Stage 2
    data.
    Verificare se infusioni mensili (ogni quattro settimane) per via endovenosa di Flebogamma® 5% DIF in un periodo di trattamento di 1 anno in soggetti affetti da PPS sono superiori al placebo valutando le prestazioni fisiche, secondo le misurazioni del test 2MWD.
    Relativamente allo Stadio 1, selezionare la dose ottimale di IVIG rispetto al placebo.
    Relativamente allo Stadio 2, stabilire la superiorità della dose selezionata di IVIG rispetto al placebo, combinando i dati derivanti dallo Stadio 1 e dallo Stadio 2.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1 year treatment
    1 anno di trattamento
    E.5.2Secondary end point(s)
    Efficacy endpoints:
    - Pain (Visual Analogue Scale [VAS] of pain) from baseline
    to the end of the treatment period.
    - HRQoL (Medical Outcomes Study 36-Item Short Form
    Health Survey [SF-36] Physical Component Summary
    [PCS]) from baseline to the end of the treatment period.
    - Endurance (Six Minutes Walk Distance [6MWD]) from
    baseline to the end of the treatment period.

    Safety endpoints will include Adverse Events (AEs), vital signs during infusions,
    physical assessments and blood tests for clinical safety.
    Endpoint di efficacia
    Dolore (scala analogica visiva [Visual Analogue Scale,VAS] del dolore) dal basale alla fine del periodo di trattamento.
    •HRQoL (indice sintetico dello stato di salute fisica [Physical Component Scale, PCS] proveniente dal questionario sullo stato di salute in forma breve a 36 punti per lo studio degli esiti medici [Medical Outcomes Study 36-Item Short Form Survey, SF-36]) dal basale alla fine del periodo di trattamento .
    •Resistenza (distanza percorsa in sei minuti di camminata [Six Minutes Walk Distance, 6MWD]) dal basale alla fine del periodo di trattamento.

    Endpoint di sicurezza comprenderanno eventi avversi (EA), i segni vitali durante l'infusione, valutazioni fisiche e esami del sangue per la sicurezza clinica.
    E.5.2.1Timepoint(s) of evaluation of this end point
    One year treatment.
    And for the one year treatments and a half year without treatment (to assess the sustainability effect).
    1 anno di trattamento . 6 mesi senza trattamento per verificare l'effetto di sostenibilità
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Il presente studio consisterà di due stadi
    It is a study trial with two stages design
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA15
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Denmark
    Germany
    Italy
    Netherlands
    Poland
    Romania
    Spain
    Sweden
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    ultima visita dell'ultimo paziente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days12
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 70
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 140
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 150
    F.4.2.2In the whole clinical trial 210
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-11-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-01-28
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 21:00:55 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA